|
Getting your Trinity Audio player ready...
|
Sept. 15, 2026 Investors looking across emerging-growth and small-cap stocks are watching Veea Inc. (NASDAQ: VEEA), Sphere 3D Corp. d/b/a DarkHorse Technologies (NASDAQ: ANY), DataMEDS AI, Inc. (NASDAQ: MEDS), MySize, Inc. (NASDAQ: MYSZ) and PDS Biotechnology Corporation (NASDAQ: PDSB) as developments spanning AI healthcare, AI infrastructure, GPU computing, defense technology and cancer immunotherapy create potential catalysts across the group.
Veea Inc. (NASDAQ: VEEA) and NovaGen Health Networks have signed a term sheet and are targeting a definitive business combination agreement within the coming weeks. The proposal includes a $10 million cornerstone investment commitment from GeoNova Capital. Built on VeeaONE, the proposed platform would combine health records, wearable and sensor data, and biological measurements into a patient-controlled health profile while supporting agentic AI applications closer to the patient.
Sphere 3D Corp. d/b/a DarkHorse Technologies (NASDAQ: ANY) is accelerating its transition toward AI infrastructure, HPC and energized data centers. Sphere recently announced a $5 million private placement, including $1 million in director participation, while agreeing to sell approximately 5,500 legacy mining machines for roughly $3.1 million. The company has also secured an option on approximately 20 acres in Hopkinsville, Kentucky, for a proposed 50 MW data center supported by a proposed 65 MW substation, as its DarkHorse strategy increasingly focuses on energized power and AI/HPC infrastructure.
Axe Compute Inc. (NASDAQ: AGPU) has completed another major step in its transition toward a pure-play neocloud GPU-as-a-Service platform, selling its legacy Helomics AI cancer diagnostics laboratory business to DataMEDS AI, Inc. (NASDAQ: MEDS) in an all-stock transaction. Axe received DataMEDS common shares and common-share equivalents, providing potential participation in DataMEDS’ future performance while allowing Axe to concentrate its operating structure on scaling GPU-as-a-Service, AI compute and neocloud infrastructure. Helomics was the final operating business remaining from Axe Compute’s former identity as Predictive Oncology.
MySize, Inc. (NASDAQ: MYSZ) has announced an acquisition-led strategy aimed at building a defense technology platform through potential acquisitions. The company plans to evaluate businesses based on technology capabilities, commercial activity, customer relationships, growth opportunities and financial profiles, potentially expanding MySize beyond its existing AI-enabled sizing, e-commerce and fashion technology operations.
PDS Biotechnology Corporation (NASDAQ: PDSB) announced the initial closing of a PIPE financing led by Nant Capital, with additional participation from current investors. The clinical-stage biotechnology company is advancing PDS0301, an investigational tumor-targeted IL-12 immunocytokine being developed for cancer immunotherapy, while also owning the Versamune® cancer vaccine platform.
Together, VEEA, ANY, MEDS, AGPU, MYSZ and PDSB span developing growth themes including agentic AI healthcare, AI data centers, neocloud GPU computing, defense technology and next-generation cancer therapeutics, putting the group in focus as their respective transactions, infrastructure projects, acquisition strategies and clinical programs advance.
About the Companies
Veea Inc. (NASDAQ: VEEA) develops edge computing, connectivity and AI-enabled technologies through its VeeaONE platform.
Sphere 3D Corp. d/b/a DarkHorse Technologies (NASDAQ: ANY) develops energized power and data center infrastructure supporting AI, HPC and digital-asset workloads.
DataMEDS AI, Inc. (NASDAQ: MEDS) is a Health IT company focused on vertically integrating health data acquisition and transfer and is acquiring Helomics, an AI-enabled functional precision medicine oncology platform.
Axe Compute Inc. (NASDAQ: AGPU) is a neocloud AI infrastructure company focused on scaling GPU-as-a-Service and AI compute capabilities.
MySize, Inc. (NASDAQ: MYSZ) operates technology and commerce businesses while pursuing an acquisition-led expansion into defense technology.
PDS Biotechnology Corporation (NASDAQ: PDSB) is a clinical-stage biotechnology company developing targeted cancer immunotherapies.
About The Street Reports
The Street Reports (TSR) is a financial media awareness platform focused on emerging-growth, small-cap, micro-cap and nano-cap companies. The Street Reports publishes and distributes market-focused content across financial news, media and digital channels, providing companies with expanded visibility and exposure to a broad audience of readers and market participants.